Novacyt Akcie

Novacyt PEG

PEG Ratio (Cena/Zisk-k-Růstu) společnosti Novacyt (ALNOV.PA) k datu 10. 8. 2026.

PEG

0,00

Poslední aktualizace:

PEG Ratio (Cena/Zisk-k-Růstu) společnosti Novacyt je 2026 0,00 . PEG Ratio (Cena/Zisk-k-Růstu) společnosti Novacyt byl 2025 0,00 . Klesá tak o % nižší než v předchozím roce.
Access this data via the Eulerpool API

Novacyt Analýza akcií

Co dělá Novacyt? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt je jednou z nejoblíbenějších společností na Eulerpool.com.

Často kladené otázky ohledně akcií Novacyt

Na Eulerpool najdete úplný historický vývoj PEG Ratio (Cena/Zisk-k-Růstu) Novacyt od roku 2006 – s ročními hodnotami, grafy a podrobnou analýzou.

Poměr PEG upravuje P/E poměr o očekávanou míru růstu zisku. PEG pod 1 může naznačovat podceňovanou akcii relativně k jejímu potenciálu růstu.

PEG = P/E poměr / Očekávaná roční míra růstu EPS

Srovnávejte ukazatele s průměry odvětví, protože se normy výrazně liší. Například marže maloobchodu jsou obecně nižší než marže softwaru.

Dobrá hodnota se liší podle odvětví a fáze vývoje společnosti. Na Eulerpool můžete porovnat Novacyt společnosti PEG Ratio (Cena/Zisk-k-Růstu) s porovnatelnými společnostmi a průměrem odvětví, abyste určili, zda je atraktivní.

Access this data via the Eulerpool API

Oceňování — Novacyt

Všechny klíčové ukazatele — Novacyt